# Phase 14 impact inspection — 2026-10-05

Baseline: `main` / `origin/main` at `5ec70b6`; working branch `codex/phase14-drug-catalog-prescriptions`.

The Phase 13 addendum, closure/API reports, MedicalEncounter, FollowUpEligibility, clinical contracts/controllers/access/mutations/read service, StartVisit, CompleteTicket, ticket response, RootGuard/SuperAdmin, ApplicationUser, security constants/seeder, EF configuration/concurrency guards, and Phase 13 domain/API/SQL Server/architecture fixtures were inspected before implementation.

Preserved rules: owning approved active Doctor and active Practice scope; authenticated patient account ownership; no administrator/Reception clinical override; completed encounter amendments; zero diagnoses permitted or exactly one primary; atomic Ticket/Encounter/follow-up completion; existing Start Visit and Complete Visit routes; append-only clinical history; existing ProblemDetails and transaction/idempotency patterns.

Impacts: append permissions without renumbering existing deterministic permission IDs; add a profile-free catalog manager account type guarded by the existing RootGuard; add separate catalog, import, request and prescription aggregates; extend encounter capabilities/blockers and Complete Visit with prescription rowversion/finalization; add an additive schema migration and localized resources. Phase 13 DEC-069's deferral of prescriptions/catalog is superseded only for the approved Phase 14 scope. No finance, dispensing, pharmacy, notifications, online sync, or cross-doctor access is added.

Validation: focused domain tests, authenticated API tests using the existing SQLite/SQL Server fixture, SQL Server constraints/concurrency/rollback tests, architecture checks, full regression suite and zero-warning solution build. README closure is conditional on all Definition of Done evidence.
